Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus
Status:
Terminated
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The study will investigate the effects of atorvastatin on the concentrations of small, dense
LDL and HDL subfractions in patients with diabetes and the underlying mechanisms of these
effects.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.